Related Experiment Video
Updated: May 10, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
The effect of recombinant human growth hormone therapy on left-ventricular chamber size and function in children with
Ihsan Esen1, Ilker Cetin, Fatma Demirel
1Department of Pediatric Endocrinology, Ankara Child's Health and Hematology Oncology Training Hospital, Irfan Bastug Cad. Kurtdereli Sok. No: 10, 06110, Altindag, Ankara, Turkey, esen_ihsan@yahoo.com.
Insights
Recombinant human growth hormone (rhGH) therapy increases heart muscle mass in children with growth hormone deficiency (GHD). This cardiac remodeling occurs without altering heart function or geometry.
Area of Science:
- Pediatric Endocrinology
- Cardiology
- Medical Imaging
Background:
- Idiopathic isolated growth hormone deficiency (GHD) can affect cardiac structure.
- Recombinant human growth hormone (rhGH) is a standard treatment for GHD.
Purpose of the Study:
- To evaluate the impact of rhGH therapy on left-ventricular (LV) size and function in children with GHD.
- To assess cardiac remodeling using echocardiography and tissue Doppler imaging (TDI).
Main Methods:
- Thirty children with GHD received rhGH therapy for 12 months.
- Conventional echocardiography and TDI were used to assess LV structure and function at baseline and follow-up intervals (3, 6, 12 months).
Main Results:
- Significant increases in LV mass (LVM) and relative wall thickness (RWT) were observed after 3 months of rhGH treatment.
- LVM normalized and showed a steady increase up to 12 months, without exceeding normal limits.
- No significant changes in LV functional parameters or interventricular septum were detected.
Conclusions:
- rhGH therapy induces concentric myocardial remodeling, increasing LV mass without adverse effects on cardiac geometry or function.
- The observed increase in myocardial mass is adaptive remodeling rather than pathological hypertrophy.
Abstract:
This study was designed to assess the effect of recombinant human growth hormone (rhGH) therapy on left-ventricular (LV) chamber size and function in children with idiopathic isolated growth hormone deficiency (GHD) using conventional echocardiography and tissue Doppler imaging (TDI). Thirty patients (19 boys and 11 girls) with idiopathic isolated GHD were followed-up for 12 months. Mean age of patients was 11.0 ± 2.6 years (range 6.3-15.5). At baseline and at 3, 6, and 12 months of treatment, the structure of the left ventricle was assessed by conventional echocardiography and myocardial rates and time intervals by TDI. There was a significant increase in LV mass (LVM) compared with pretreatment values. Like LVM, relative wall thickness (RWT) was also increased significantly. The significant increase in LVM indexed to body surface area and RWT became apparent at month 3 of treatment with a significant increase in LVM indexed to height(2.7) at treatment month 6. Normalized LVM increased as early month 3 of treatment, and a steady increase was observed until month 12. However, no patient had LVM > +2 standard deviation scores at month 12 of treatment. No significant differences were observed in functional parameters of the left ventricle and the interventricular septum. The results of this study showed that rhGH therapy causes an increase in myocardial mass without changing the geometry or function of the myocardium. Therefore, the increase in myocardial mass appears to be concentric, thus causing remodeling instead of hypertrophy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cellular Adaptation II: Hypertrophy
Heart Failure II: Pathophysiology
